资讯

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key ...
FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19 million, ...